↑ DOR expected

↔ ATV expected

↔ EFV expected

↓ ATV possible

↓ COBI possible

↑ ETR possible↓ ATV possible

↓ COBI possible

↑ RPV PO possible

↔ ATV expected

ATV/c in ART-Naive Patients:

• ATV 400 mg plus COBI 150 mg once daily
• Do not use coformulated ATV 300 mg/COBI 150 mg.

ATV/c in ART-Experienced Patients:

• Do not coadminister.

No dose adjustment needed for EFV.

↑ DOR expected

↔ ATV expected

↔ EFV expected

(ATV 400 mg plus RTV 100 mg) Once Daily:

• ATV concentrations similar to (ATV 300 mg plus RTV 100 mg) without EFV

(ATV 300 mg plus RTV 100 mg) Once Daily:

• ETR AUC and Cmin both ↑ ~30%
• ↔ ATV AUC and Cmin

↑ RPV PO possible

↔ ATV expected

ATV/r in ART-Naive Patients:

• (ATV 400 mg plus RTV 100 mg) once daily

ATV/r in ART-Experienced Patients:

• Do not coadminister.

No dose adjustment needed for EFV.

↑ DOR expected

↔ DRV expected

↔ EFV expected

↓ DRV possible

↓ COBI possible

ETR 400 mg Once Daily with (DRV 800 mg plus COBI 150 mg) Once Daily:

• ↔ ETR AUC and Cmin
• ↔ DRV AUC and Cmin ↓ 56%
• COBI AUC ↓ 30% and Cmin ↓ 66%

↔ DRV expected

↑ RPV PO possible

↑ DOR expected

↔ DRV expected

With (DRV 300 mg plus RTV 100 mg) Twice Daily:

• EFV AUC ↑ 21%
• ↔ DRV AUC and Cmin ↓ 31%

ETR 100 mg Twice Daily with (DRV 600 mg plus RTV 100 mg) Twice Daily:

• ETR AUC ↓ 37% and Cmin ↓ 49%
• ↔ DRV

RPV 150 mg PO Once Daily with (DRV 800 mg plus RTV 100 mg) Once Daily:

• RPV PO AUC ↑ 130% and Cmin ↑ 178%
• ↔ DRV^a

No dose adjustment needed.

Despite reduced ETR concentration, safety and efficacy of this combination have been established in a clinical trial.